

**Experiment Number:** 20006 - 03  
**Test Type:** CHRONIC  
**Route:** GAVAGE  
**Species/Strain:** RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Indole-3-carbinol  
**CAS Number:** 700-06-1

**Date Report Requested:** 04/16/2013  
**Time Report Requested:** 09:53:55  
**First Dose M/F:** 03/14/07 / 03/15/07  
**Lab:** BAT

F1\_HSD

**NTP Study Number:** C20006B  
**Lock Date:** 06/21/2010  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 3.0.1.1\_001  
**PWG Approval Date:** NONE

Experiment Number: 20006 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol  
CAS Number: 700-06-1

Date Report Requested: 04/16/2013

Time Report Requested: 09:53:55

First Dose M/F: 03/14/07 / 03/15/07

Lab: BAT

Harlan Sprague Dawley RATS MALE

0 mg/kg

75 mg/kg

150 mg/kg

300 mg/kg

**Disposition Summary**

<b>Animals Initially In Study</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>
<b>Early Deaths</b>				
<b>Dosing Accident</b>				<b>1</b>
<b>Moribund Sacrifice</b>	<b>14</b>	<b>23</b>	<b>15</b>	<b>20</b>
<b>Natural Death</b>	<b>16</b>	<b>14</b>	<b>18</b>	<b>17</b>
<b>Survivors</b>				
<b>Terminal Sacrifice</b>	<b>20</b>	<b>13</b>	<b>17</b>	<b>12</b>
<b>Animals Examined Microscopically</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>

## ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Inflammation		1 (2%)		
Epithelium, Hyperplasia		1 (2%)		
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid		1 (2%)		
Necrosis	1 (2%)	1 (2%)		
Intestine Large, Colon	(50)	(50)	(50)	(50)
Erosion	1 (2%)			
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Fibrosis				1 (2%)
Intestine Small, Duodenum	(43)	(48)	(47)	(48)
Lymphatic, Ectasia			15 (32%)	14 (29%)
Intestine Small, Ileum	(35)	(43)	(42)	(38)
Intestine Small, Jejunum	(40)	(39)	(40)	(42)
Lymphatic, Ectasia		2 (5%)	27 (68%)	41 (98%)
Liver	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)			
Basophilic Focus	3 (6%)		3 (6%)	1 (2%)
Cholangiofibrosis		1 (2%)	3 (6%)	1 (2%)
Clear Cell Focus	14 (28%)	13 (26%)	18 (36%)	9 (18%)
Degeneration, Cystic			1 (2%)	
Eosinophilic Focus	10 (20%)	12 (24%)	10 (20%)	6 (12%)
Hepatodiaphragmatic Nodule	2 (4%)		1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20006 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 04/16/2013

Time Report Requested: 09:53:55

First Dose M/F: 03/14/07 / 03/15/07

Lab: BAT

Harlan Sprague Dawley RATS MALE	0 mg/kg	75 mg/kg	150 mg/kg	300 mg/kg
Mixed Cell Focus	4 (8%)	2 (4%)	1 (2%)	2 (4%)
Necrosis	3 (6%)	3 (6%)	5 (10%)	7 (14%)
Artery, Inflammation, Chronic Active		1 (2%)		
Bile Duct, Cyst			1 (2%)	5 (10%)
Bile Duct, Cyst, Multiple			1 (2%)	
Bile Duct, Fibrosis	2 (4%)		1 (2%)	1 (2%)
Bile Duct, Hyperplasia	7 (14%)	4 (8%)	3 (6%)	3 (6%)
Oval Cell, Hyperplasia				1 (2%)
Periportal, Inflammation, Chronic Active	1 (2%)			
Mesentery	(2)	(2)	(1)	(0)
Artery, Inflammation, Chronic Active	1 (50%)			
Artery, Mineralization		1 (50%)		
Fat, Necrosis	1 (50%)			
Oral Mucosa	(50)	(50)	(50)	(50)
Foreign Body		1 (2%)		
Hyperplasia, Squamous		1 (2%)	2 (4%)	1 (2%)
Sebaceous Gland, Ectopic Tissue				1 (2%)
Pancreas	(50)	(50)	(50)	(49)
Angiectasis				1 (2%)
Thrombosis		1 (2%)		
Acinus, Atrophy	1 (2%)	1 (2%)		2 (4%)
Acinus, Hyperplasia	16 (32%)	10 (20%)	14 (28%)	10 (20%)
Artery, Inflammation, Chronic Active	22 (44%)	32 (64%)	27 (54%)	21 (43%)
Salivary Glands	(50)	(50)	(49)	(50)
Metaplasia		1 (2%)		2 (4%)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Erosion			1 (2%)	
Hyperplasia	19 (38%)	19 (38%)	19 (38%)	22 (44%)
Inflammation	2 (4%)		4 (8%)	1 (2%)
Necrosis	1 (2%)			
Ulcer	2 (4%)	1 (2%)	1 (2%)	1 (2%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Epithelium, Amyloid Deposition			1 (2%)	
Epithelium, Hyperplasia	2 (4%)	5 (10%)	7 (14%)	3 (6%)
Epithelium, Inflammation		1 (2%)		
Epithelium, Inflammation, Chronic Active	3 (6%)	4 (8%)	2 (4%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20006 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 04/16/2013

Time Report Requested: 09:53:55

First Dose M/F: 03/14/07 / 03/15/07

Lab: BAT

Harlan Sprague Dawley RATS MALE	0 mg/kg	75 mg/kg	150 mg/kg	300 mg/kg
Epithelium, Mineralization	7 (14%)	12 (24%)	6 (12%)	10 (20%)
Epithelium, Necrosis	1 (2%)			
Epithelium, Ulcer		1 (2%)		
Epithelium, Muscularis, Hyperplasia, Focal		1 (2%)		
Tongue	(0)	(0)	(0)	(1)
Tooth	(1)	(0)	(1)	(0)
Malformation			1 (100%)	
Necrosis	1 (100%)			

## CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(50)	(50)	(50)
Dilatation	1 (2%)			
Inflammation, Chronic Active	30 (60%)	38 (76%)	30 (60%)	29 (58%)
Mineralization		2 (4%)	1 (2%)	1 (2%)
Thrombosis			1 (2%)	
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	47 (94%)	48 (96%)	49 (98%)	48 (96%)
Mineralization	1 (2%)			1 (2%)
Atrium, Thrombosis	1 (2%)	3 (6%)	3 (6%)	3 (6%)
Epicardium, Inflammation	1 (2%)	1 (2%)		
Pericardium, Inflammation			1 (2%)	

## ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(49)	(50)	(50)
Atrophy				1 (2%)
Degeneration, Cystic	4 (8%)	3 (6%)	5 (10%)	4 (8%)
Degeneration, Fatty	8 (16%)	13 (27%)	5 (10%)	16 (32%)
Hematopoietic Cell Proliferation			1 (2%)	
Hemorrhage			1 (2%)	
Hyperplasia	14 (28%)	19 (39%)	19 (38%)	6 (12%)
Necrosis	1 (2%)			2 (4%)
Thrombosis		1 (2%)		
Adrenal Medulla	(50)	(49)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20006 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Indole-3-carbinol  
CAS Number: 700-06-1

Date Report Requested: 04/16/2013

Time Report Requested: 09:53:55

First Dose M/F: 03/14/07 / 03/15/07

Lab: BAT

---

Harlan Sprague Dawley RATS MALE	0 mg/kg	75 mg/kg	150 mg/kg	300 mg/kg
Angiectasis	1 (2%)			
Degeneration, Fatty		1 (2%)		
Hyperplasia	18 (36%)	22 (45%)	20 (40%)	19 (38%)
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	3 (6%)	6 (12%)	1 (2%)	3 (6%)
Parathyroid Gland	(43)	(46)	(50)	(47)
Hyperplasia	3 (7%)	10 (22%)	13 (26%)	8 (17%)
Pituitary Gland	(50)	(49)	(50)	(47)
Pars Distalis, Hyperplasia	17 (34%)	18 (37%)	19 (38%)	12 (26%)
Thyroid Gland	(50)	(46)	(48)	(47)
Thrombosis	1 (2%)			
C-cell, Hyperplasia	6 (12%)	4 (9%)	4 (8%)	5 (11%)
C-cell, Hypertrophy				1 (2%)
Follicular Cell, Hyperplasia		1 (2%)		
Follicular Cell, Hypertrophy	21 (42%)	34 (74%)	33 (69%)	36 (77%)

---

GENERAL BODY SYSTEM

None

---

GENITAL SYSTEM

Epididymis	(50)	(50)	(50)	(50)
Atrophy	1 (2%)			
Preputial Gland	(50)	(50)	(49)	(50)
Cyst	7 (14%)		3 (6%)	5 (10%)
Fibrosis	1 (2%)			
Inflammation	2 (4%)			1 (2%)
Prostate	(50)	(50)	(50)	(50)
Atrophy	1 (2%)	1 (2%)		
Fibrosis	1 (2%)	3 (6%)	2 (4%)	1 (2%)
Hyperplasia	3 (6%)	4 (8%)	7 (14%)	3 (6%)
Inflammation, Acute	1 (2%)	6 (12%)		6 (12%)
Inflammation, Chronic Active				1 (2%)
Necrosis	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20006 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol  
CAS Number: 700-06-1

Date Report Requested: 04/16/2013

Time Report Requested: 09:53:55

First Dose M/F: 03/14/07 / 03/15/07

Lab: BAT

Harlan Sprague Dawley RATS MALE	0 mg/kg	75 mg/kg	150 mg/kg	300 mg/kg
Seminal Vesicle	(49)	(50)	(50)	(50)
Hypoplasia			1 (2%)	
Inflammation, Acute				2 (4%)
Testes	(49)	(50)	(50)	(50)
Atrophy	30 (61%)	37 (74%)	35 (70%)	33 (66%)
Pigmentation, Hemosiderin			1 (2%)	
Artery, Inflammation, Chronic Active	28 (57%)	34 (68%)	33 (66%)	33 (66%)
Interstitial Cell, Hyperplasia	1 (2%)		1 (2%)	2 (4%)

## HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)
Hyperplasia	1 (2%)	2 (4%)	4 (8%)	3 (6%)
Lymph Node	(4)	(8)	(8)	(6)
Angiectasis				1 (17%)
Bronchial, Hemorrhage		1 (13%)	1 (13%)	
Deep Cervical, Hemorrhage		1 (13%)		
Deep Cervical, Hyperplasia, Plasma Cell		1 (13%)		
Deep Cervical, Inflammation		1 (13%)		
Iliac, Infiltration Cellular, Histiocyte			1 (13%)	
Lumbar, Hemorrhage			2 (25%)	
Mediastinal, Ectasia		1 (13%)	1 (13%)	
Mediastinal, Hemorrhage	1 (25%)	2 (25%)	3 (38%)	1 (17%)
Mediastinal, Hyperplasia, Lymphoid		1 (13%)		
Mediastinal, Infiltration Cellular, Lipocyte				1 (17%)
Mediastinal, Infiltration Cellular, Histiocyte		1 (13%)		
Mediastinal, Pigmentation, Hemosiderin				1 (17%)
Pancreatic, Hemorrhage		1 (13%)		1 (17%)
Renal, Ectasia	2 (50%)			
Renal, Hemorrhage	1 (25%)	2 (25%)		
Renal, Pigmentation, Hemosiderin				1 (17%)
Lymph Node, Mandibular	(50)	(50)	(49)	(50)
Ectasia		1 (2%)	1 (2%)	1 (2%)
Hemorrhage			1 (2%)	
Hyperplasia, Plasma Cell	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20006 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Indole-3-carbinol  
CAS Number: 700-06-1

Date Report Requested: 04/16/2013

Time Report Requested: 09:53:55

First Dose M/F: 03/14/07 / 03/15/07

Lab: BAT

Harlan Sprague Dawley RATS MALE	0 mg/kg	75 mg/kg	150 mg/kg	300 mg/kg
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)
Ectasia		1 (2%)		
Hemorrhage		1 (2%)		
Hyperplasia, Lymphoid	1 (2%)			1 (2%)
Lymphatic, Ectasia			1 (2%)	5 (10%)
Spleen	(50)	(50)	(50)	(50)
Atrophy				1 (2%)
Hematopoietic Cell Proliferation	28 (56%)	33 (66%)	28 (56%)	29 (58%)
Inflammation	1 (2%)			
Necrosis			1 (2%)	
Thymus	(46)	(49)	(49)	(47)
Atrophy	41 (89%)	41 (84%)	42 (86%)	41 (87%)
Hemorrhage			1 (2%)	
Epithelial Cell, Hyperplasia	1 (2%)			
<b>INTEGUMENTARY SYSTEM</b>				
Mammary Gland	(50)	(50)	(50)	(50)
Fibrosis			1 (2%)	
Inflammation				1 (2%)
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion	5 (10%)	3 (6%)	2 (4%)	2 (4%)
Inflammation	3 (6%)	2 (4%)		2 (4%)
Necrosis		2 (4%)		
Epidermis, Ulcer	1 (2%)			
Sebaceous Gland, Hyperplasia				1 (2%)
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(50)	(50)
Fibrous Osteodystrophy	12 (24%)	19 (38%)	13 (26%)	8 (16%)
Maxilla, Fracture			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20006 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 04/16/2013

Time Report Requested: 09:53:55

First Dose M/F: 03/14/07 / 03/15/07

Lab: BAT

Harlan Sprague Dawley RATS MALE	0 mg/kg	75 mg/kg	150 mg/kg	300 mg/kg
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion				1 (2%)
Gliosis		2 (4%)		
Necrosis				2 (4%)
Spinal Cord	(0)	(2)	(1)	(0)
Degeneration		2 (100%)	1 (100%)	
<b>RESPIRATORY SYSTEM</b>				
Lung	(49)	(50)	(50)	(50)
Edema			1 (2%)	1 (2%)
Fibrosis				1 (2%)
Foreign Body		1 (2%)	1 (2%)	
Hemorrhage			1 (2%)	1 (2%)
Hemorrhage, Multifocal	3 (6%)	3 (6%)	7 (14%)	7 (14%)
Inflammation, Granulomatous			1 (2%)	
Inflammation, Chronic	17 (35%)	21 (42%)	24 (48%)	23 (46%)
Mineralization				1 (2%)
Necrosis	1 (2%)			
Alveolar Epithelium, Hyperplasia	1 (2%)		1 (2%)	1 (2%)
Alveolus, Infiltration Cellular, Histiocyte	19 (39%)	22 (44%)	19 (38%)	13 (26%)
Alveolus, Mineralization	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Nose	(50)	(50)	(50)	(50)
Foreign Body	4 (8%)	12 (24%)	11 (22%)	10 (20%)
Fungus	1 (2%)			
Inflammation	1 (2%)			
Inflammation, Chronic Active	11 (22%)	15 (30%)	16 (32%)	15 (30%)
Thrombosis		1 (2%)		
Respiratory Epithelium, Hyperplasia	2 (4%)	2 (4%)	4 (8%)	7 (14%)
Respiratory Epithelium, Metaplasia, Squamous			2 (4%)	
Trachea	(50)	(50)	(50)	(50)
Inflammation	1 (2%)	1 (2%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 20006 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/HSD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 04/16/2013

Time Report Requested: 09:53:55

First Dose M/F: 03/14/07 / 03/15/07

Lab: BAT

---

Harlan Sprague Dawley RATS MALE

0 mg/kg

75 mg/kg

150 mg/kg

300 mg/kg

---

SPECIAL SENSES SYSTEM

Ear	(0)	(0)	(1)	(0)
External Ear, Hyperplasia, Squamous			1 (100%)	
Eye	(50)	(50)	(49)	(49)
Cataract				1 (2%)
Anterior Chamber, Inflammation, Acute	2 (4%)	1 (2%)	4 (8%)	3 (6%)
Cornea, Inflammation, Acute	20 (40%)	25 (50%)	17 (35%)	21 (43%)
Retina, Fibrosis				1 (2%)
Harderian Gland	(50)	(50)	(49)	(50)
Angiectasis				1 (2%)
Pigmentation, Porphyrin	1 (2%)			
Lacrimal Gland	(1)	(2)	(4)	(0)
Degeneration	1 (100%)	2 (100%)	4 (100%)	

---

URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)
Cyst				1 (2%)
Metaplasia, Osseous		1 (2%)		
Nephropathy	50 (100%)	49 (98%)	49 (98%)	50 (100%)
Renal Tubule, Dilatation			1 (2%)	
Urinary Bladder	(50)	(50)	(50)	(50)
Hemorrhage				1 (2%)
Inflammation				1 (2%)

---

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20006 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 04/16/2013

Time Report Requested: 09:53:55

First Dose M/F: 03/14/07 / 03/15/07

Lab: BAT

Harlan Sprague Dawley RATS FEMALE

0 mg/kg

75 mg/kg

150 mg/kg

300 mg/kg

## Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Dosing Accident		1		1
Moribund Sacrifice	24	22	23	11
Natural Death	5	8	7	8
Survivors				
Moribund Sacrifice		1	1	
Terminal Sacrifice	21	18	19	30
Animals Examined Microscopically	50	50	50	50

## ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Inflammation		2 (4%)		
Perforation				1 (2%)
Intestine Large, Cecum	(50)	(50)	(50)	(48)
Intestine Large, Colon	(50)	(50)	(50)	(48)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Metaplasia			1 (2%)	
Intestine Small, Duodenum	(48)	(47)	(48)	(47)
Lymphatic, Ectasia			16 (33%)	38 (81%)
Intestine Small, Ileum	(47)	(47)	(48)	(47)
Intestine Small, Jejunum	(47)	(46)	(48)	(48)
Lymphatic, Ectasia			30 (63%)	47 (98%)
Liver	(50)	(50)	(50)	(48)
Angiectasis	1 (2%)		2 (4%)	3 (6%)
Basophilic Focus	14 (28%)	6 (12%)	11 (22%)	14 (29%)
Cholangiofibrosis		1 (2%)		
Clear Cell Focus	6 (12%)	7 (14%)	4 (8%)	18 (38%)
Eosinophilic Focus		4 (8%)	5 (10%)	6 (13%)
Hepatodiaphragmatic Nodule			3 (6%)	2 (4%)
Inflammation, Chronic				1 (2%)
Mixed Cell Focus	5 (10%)	1 (2%)	5 (10%)	4 (8%)
Necrosis	1 (2%)	2 (4%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20006 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 04/16/2013

Time Report Requested: 09:53:55

First Dose M/F: 03/14/07 / 03/15/07

Lab: BAT

Harlan Sprague Dawley RATS FEMALE	0 mg/kg	75 mg/kg	150 mg/kg	300 mg/kg
Pigmentation	1 (2%)			
Thrombosis		1 (2%)		
Bile Duct, Cyst	2 (4%)	1 (2%)	4 (8%)	4 (8%)
Bile Duct, Cyst, Multiple	2 (4%)	1 (2%)	2 (4%)	2 (4%)
Bile Duct, Hyperplasia	2 (4%)			
Centrilobular, Degeneration		1 (2%)		
Mesentery	(0)	(2)	(2)	(1)
Artery, Inflammation, Chronic Active		1 (50%)		
Oral Mucosa	(50)	(50)	(50)	(50)
Hyperplasia, Squamous			1 (2%)	2 (4%)
Pancreas	(50)	(49)	(49)	(48)
Acinus, Hyperplasia	1 (2%)	3 (6%)		1 (2%)
Artery, Inflammation, Chronic Active	1 (2%)	4 (8%)	3 (6%)	6 (13%)
Salivary Glands	(50)	(49)	(48)	(50)
Inflammation	1 (2%)			
Stomach, Forestomach	(50)	(50)	(50)	(49)
Hyperplasia	2 (4%)	5 (10%)	7 (14%)	3 (6%)
Inflammation	1 (2%)			1 (2%)
Pigmentation, Melanin		1 (2%)		
Ulcer	1 (2%)			
Stomach, Glandular	(50)	(49)	(50)	(49)
Erosion			1 (2%)	
Ulcer	1 (2%)			
Epithelium, Hyperplasia	1 (2%)		1 (2%)	
Epithelium, Mineralization			1 (2%)	
Tongue	(1)	(1)	(0)	(1)
Cyst				1 (100%)
Erosion	1 (100%)			
Inflammation		1 (100%)		
Tooth	(0)	(1)	(0)	(0)

## CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(50)	(50)	(50)
Degeneration, Focal			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20006 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 04/16/2013

Time Report Requested: 09:53:55

First Dose M/F: 03/14/07 / 03/15/07

Lab: BAT

Harlan Sprague Dawley RATS FEMALE	0 mg/kg	75 mg/kg	150 mg/kg	300 mg/kg
Inflammation, Chronic Active	1 (2%)	3 (6%)	4 (8%)	7 (14%)
Thrombosis			1 (2%)	
Heart	(50)	(50)	(50)	(49)
Cardiomyopathy	24 (48%)	24 (48%)	24 (48%)	24 (49%)
Atrium, Thrombosis		1 (2%)		
Epicardium, Inflammation	1 (2%)	3 (6%)		1 (2%)
Pericardium, Inflammation			2 (4%)	

## ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(50)	(48)
Degeneration, Cystic	16 (32%)	12 (24%)	11 (22%)	15 (31%)
Degeneration, Fatty	5 (10%)	3 (6%)		1 (2%)
Hyperplasia	18 (36%)	11 (22%)	18 (36%)	15 (31%)
Hypertrophy	1 (2%)			
Inflammation		1 (2%)		1 (2%)
Necrosis			1 (2%)	1 (2%)
Thrombosis		1 (2%)	1 (2%)	
Bilateral, Degeneration, Cystic	1 (2%)			
Adrenal Medulla	(50)	(50)	(50)	(48)
Hyperplasia	15 (30%)	13 (26%)	11 (22%)	12 (25%)
Islets, Pancreatic	(50)	(50)	(50)	(50)
Parathyroid Gland	(47)	(49)	(46)	(49)
Hyperplasia		2 (4%)		
Pituitary Gland	(50)	(50)	(50)	(49)
Pars Distalis, Hyperplasia	19 (38%)	14 (28%)	18 (36%)	24 (49%)
Thyroid Gland	(49)	(49)	(48)	(47)
C-cell, Hyperplasia	7 (14%)	5 (10%)	6 (13%)	5 (11%)
Follicular Cell, Hyperplasia	1 (2%)		1 (2%)	1 (2%)
Follicular Cell, Hypertrophy	27 (55%)	23 (47%)	24 (50%)	30 (64%)

## GENERAL BODY SYSTEM

None

a - Number of animals examined microscopically at site and number of animals with lesion

Harlan Sprague Dawley RATS FEMALE	0 mg/kg	75 mg/kg	150 mg/kg	300 mg/kg
<b>GENITAL SYSTEM</b>				
Clitoral Gland	(50)	(50)	(50)	(50)
Cyst	5 (10%)	2 (4%)	3 (6%)	4 (8%)
Inflammation	1 (2%)			2 (4%)
Ovary	(50)	(50)	(50)	(49)
Angiectasis				1 (2%)
Atrophy	40 (80%)	23 (46%)	37 (74%)	30 (61%)
Cyst	17 (34%)	13 (26%)	16 (32%)	16 (33%)
Inflammation, Acute			1 (2%)	1 (2%)
Inflammation, Chronic				1 (2%)
Inflammation, Chronic Active	1 (2%)	1 (2%)		1 (2%)
Necrosis, Fibrinoid			1 (2%)	
Uterus	(50)	(50)	(50)	(50)
Cyst			2 (4%)	
Dilatation	9 (18%)	9 (18%)	7 (14%)	5 (10%)
Inflammation, Histiocytic, Focal	1 (2%)			
Inflammation, Acute	5 (10%)	12 (24%)	6 (12%)	9 (18%)
Thrombosis			1 (2%)	1 (2%)
Endometrium, Hyperplasia, Cystic	29 (58%)	28 (56%)	29 (58%)	21 (42%)
Endometrium, Metaplasia, Squamous	12 (24%)	18 (36%)	20 (40%)	11 (22%)
Vagina	(2)	(1)	(0)	(2)

**HEMATOPOIETIC SYSTEM**

Bone Marrow	(50)	(50)	(50)	(50)
Atrophy		1 (2%)	1 (2%)	
Hyperplasia	21 (42%)	20 (40%)	23 (46%)	17 (34%)
Lymph Node	(7)	(6)	(4)	(3)
Axillary, Hyperplasia, Lymphoid				1 (33%)
Iliac, Hyperplasia, Lymphoid		1 (17%)		
Iliac, Infiltration Cellular, Histiocyte				1 (33%)
Inguinal, Hemorrhage		1 (17%)		
Inguinal, Hyperplasia, Lymphoid	1 (14%)		1 (25%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20006 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 04/16/2013

Time Report Requested: 09:53:55

First Dose M/F: 03/14/07 / 03/15/07

Lab: BAT

Harlan Sprague Dawley RATS FEMALE	0 mg/kg	75 mg/kg	150 mg/kg	300 mg/kg
Lumbar, Hemorrhage	2 (29%)	1 (17%)		
Lumbar, Hyperplasia, Lymphoid	1 (14%)	1 (17%)		
Lumbar, Infiltration Cellular, Histiocyte		1 (17%)	1 (25%)	
Mediastinal, Ectasia			1 (25%)	
Mediastinal, Hemorrhage	2 (29%)		1 (25%)	
Mediastinal, Infiltration Cellular, Histiocyte	1 (14%)			
Lymph Node, Mandibular	(50)	(49)	(49)	(50)
Lymph Node, Mesenteric	(50)	(50)	(50)	(48)
Hemorrhage				1 (2%)
Pigmentation, Hemosiderin	1 (2%)			
Lymphatic, Ectasia			1 (2%)	15 (31%)
Spleen	(50)	(50)	(50)	(48)
Hematopoietic Cell Proliferation	36 (72%)	32 (64%)	40 (80%)	33 (69%)
Thymus	(47)	(50)	(49)	(50)
Atrophy	38 (81%)	31 (62%)	34 (69%)	38 (76%)
Hemorrhage				1 (2%)
Inflammation		1 (2%)	1 (2%)	
Epithelial Cell, Hyperplasia	1 (2%)	4 (8%)	3 (6%)	

## INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(50)	(50)	(50)
Galactocele	1 (2%)			
Hyperplasia	8 (16%)	3 (6%)	7 (14%)	7 (14%)
Inflammation	1 (2%)	1 (2%)		
Inflammation, Chronic	1 (2%)			
Duct, Dilatation	1 (2%)			
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion		1 (2%)		1 (2%)
Fibrosis				1 (2%)

## MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(50)
Fibrous Osteodystrophy		1 (2%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20006 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Indole-3-carbinol  
CAS Number: 700-06-1

Date Report Requested: 04/16/2013

Time Report Requested: 09:53:55

First Dose M/F: 03/14/07 / 03/15/07

Lab: BAT

Harlan Sprague Dawley RATS FEMALE	0 mg/kg	75 mg/kg	150 mg/kg	300 mg/kg
Skeletal Muscle Degeneration	(1)	(0)	(1) 1 (100%)	(1)
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Gliosis		1 (2%)		
Hemorrhage				1 (2%)
Inflammation		1 (2%)		
Necrosis	1 (2%)			1 (2%)
Meninges, Pigmentation, Lipofuscin		1 (2%)		
Peripheral Nerve	(0)	(2)	(0)	(0)
Spinal Cord	(0)	(1)	(0)	(0)
Hemorrhage		1 (100%)		
Necrosis		1 (100%)		
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(50)	(49)
Atelectasis		1 (2%)		
Foreign Body		2 (4%)		
Inflammation, Granulomatous	1 (2%)			
Inflammation, Chronic	34 (68%)	30 (60%)	38 (76%)	35 (71%)
Alveolar Epithelium, Hyperplasia				1 (2%)
Alveolar Epithelium, Metaplasia, Squamous				1 (2%)
Alveolus, Infiltration Cellular, Histiocyte	13 (26%)	16 (32%)	11 (22%)	9 (18%)
Bronchiole, Hyperplasia		1 (2%)	1 (2%)	
Mediastinum, Inflammation		1 (2%)		
Pleura, Inflammation, Chronic Active		1 (2%)		
Nose	(49)	(50)	(49)	(50)
Angiectasis			1 (2%)	
Foreign Body	3 (6%)	2 (4%)	3 (6%)	3 (6%)
Inflammation, Chronic Active	5 (10%)	4 (8%)	5 (10%)	6 (12%)
Glands, Olfactory Epithelium, Hyperplasia		1 (2%)		
Olfactory Epithelium, Atrophy			2 (4%)	5 (10%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20006 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 04/16/2013

Time Report Requested: 09:53:55

First Dose M/F: 03/14/07 / 03/15/07

Lab: BAT

---

Harlan Sprague Dawley RATS FEMALE	0 mg/kg	75 mg/kg	150 mg/kg	300 mg/kg
Olfactory Epithelium, Degeneration	1 (2%)		1 (2%)	
Respiratory Epithelium, Hyperplasia			3 (6%)	2 (4%)
Respiratory Epithelium, Metaplasia, Squamous			1 (2%)	1 (2%)
Trachea Epithelium, Necrosis	(50)	(50)	(50)	(50)
<hr/>				
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Cataract	1 (2%)			
Inflammation		1 (2%)	1 (2%)	
Harderian Gland	(50)	(50)	(50)	(50)
Hyperplasia, Focal			1 (2%)	
Inflammation		1 (2%)		
<hr/>				
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(48)
Nephropathy	45 (90%)	41 (82%)	42 (84%)	43 (90%)
Pelvis, Inflammation				1 (2%)
Urinary Bladder	(49)	(50)	(50)	(50)
Hyperplasia			1 (2%)	

---

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion